Product image of Oftan Flurekain (Oxybuprocaine Hydrochloride, Fluorescein Sodium) supplied by GNH India

Oftan Flurekain

Active Ingredient:
Oxybuprocaine Hydrochloride, Fluorescein Sodium
Origin:
EU

Oftan Flurekain (Oxybuprocaine Hydrochloride, Fluorescein Sodium)

Oxybuprocaine Hydrochloride / Fluorescein Sodium, the active ingredient in Oftan Flurekain, is a local anesthetic presented as an ocular solution for ocular use. It provides reversible surface anesthesia for diagnostic eye procedures and stains the corneal epithelium to highlight defects.
GNH India supplies Oftan Flurekain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Santen Oy

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Oftan Flurekain, an ophthalmic local anesthetic and corneal stain, is employed in ocular diagnostic and therapeutic procedures.

  • Tonometry: provides temporary corneal anesthesia to facilitate accurate intra‑ocular pressure measurement.
  • Slit‑lamp examination: anesthetizes the ocular surface allowing detailed examination without discomfort.
  • Corneal staining: fluorescein component highlights epithelial defects, abrasions or foreign bodies for visualization.

How It Works

  • Oxybuprocaine blocks voltage‑gated sodium channels in ocular nerve endings, producing reversible surface anesthesia, while fluorescein sodium binds to corneal proteins and fluoresces under cobalt‑blue light, enabling visualization of epithelial defects and tear‑film dynamics.

Side Effects

Common Side Effects

  • Burning or stinging sensation on instillation.
  • Transient redness or conjunctival hyperemia.
  • Increased tearing or watery discharge.
  • Mild blurred vision lasting a few minutes.
  • Temporary eyelid swelling.
  • Mild allergic conjunctivitis.

Serious or Rare Side Effects

  • Corneal epithelial toxicity or ulceration.
  • Severe allergic reaction including anaphylaxis.
  • Persistent corneal inflammation or keratitis.
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Vision loss due to corneal damage.
  • Intra‑ocular inflammation (uveitis).

Precautions & Warnings

Before using Oftan Flurekain, consider the following precautions:

  • Allergy assessment: avoid in patients with known hypersensitivity to oxybuprocaine, fluorescein or related compounds.
  • Contact lens wear: remove lenses prior to administration to prevent drug retention.
  • Pre‑existing ocular surface disease: use with caution in patients with corneal ulcers or severe dry eye.
  • Pediatric use: limit to supervised administration; dosing is determined by the clinician.
  • Pregnancy and lactation: safety not established; weigh benefits against potential risks.
  • Store at room temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Oftan Flurekain may interact with other ophthalmic agents.

Major Interactions (Avoid)

  • Concurrent use with other topical ocular anesthetics may cause additive toxicity.
  • Combination with ophthalmic solutions containing preservatives that increase irritation.
  • Simultaneous use of multiple fluorescein‑containing products may lead to overstaining.

Moderate Interactions (Monitor Closely)

  • Co‑administration with anti‑inflammatory eye drops may alter drug absorption.
  • Use with beta‑blocker eye drops may affect intra‑ocular pressure measurement accuracy.
  • Combination with ocular antibiotics may increase risk of corneal toxicity.

Frequently Asked Questions

Oftan Flurekain is a prescription ophthalmic solution that provides temporary surface anesthesia for diagnostic eye procedures such as tonometry and slit‑lamp examination, and it contains fluorescein sodium to stain the corneal epithelium, allowing clinicians to detect abrasions, foreign bodies, or other epithelial defects.

Oxybuprocaine blocks voltage‑gated sodium channels on ocular nerve endings, preventing the initiation and propagation of nerve impulses. This results in a reversible loss of sensation on the corneal surface, allowing painless examination or minor procedures.

The specific dose and frequency are determined by the prescribing clinician based on the intended procedure. Typically, a single drop is instilled onto the ocular surface shortly before the diagnostic test, and the amount may be repeated if required by the examiner.

Safety data for pregnancy and lactation are limited. The product should only be used when the potential benefit justifies any possible risk to the mother or infant, and the decision should be made by the treating ophthalmologist in consultation with the patient.

Enquiries can be submitted on the product page at gnhindia.com by entering the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with alternatives such as proparacaine or tetracaine, Oxybuprocaine provides rapid onset of anesthesia with a short duration, which is useful for brief diagnostic procedures. The addition of fluorescein offers the dual benefit of corneal staining, a feature not present in many single‑agent anesthetic drops.

The solution should be stored at room temperature, protected from direct light and moisture. Keep the vial tightly sealed in its original packaging until use, and discard any remaining product after the labeled expiration date.

The product is applied as a sterile drop onto the conjunctival sac of the eye. The patient should be instructed to blink gently after instillation to spread the solution evenly across the corneal surface before the diagnostic procedure begins.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, corneal epithelial toxicity leading to ulceration, and significant intra‑ocular inflammation. Any signs of intense pain, vision loss, or persistent redness should prompt immediate medical evaluation.

Patients with a known hypersensitivity to oxybuprocaine, fluorescein, or any excipients in the formulation should avoid the product. It is also contraindicated in individuals with active corneal infections, severe epithelial defects, or uncontrolled ocular surface disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Oxybuprocaine Hydrochloride, Fluorescein Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT